Mesoporous Silicon in Drug Delivery Applications

Salonen, Jarno; Kaukonen, Ann Marie; Hirvonen, Jouni; Lehto, Vesa‐Pekka

doi:10.1002/jps.20999

Cited by 419 publications

(355 citation statements)

References 165 publications

Supporting

Mentioning

348

Contrasting

Unclassified

Order By: Relevance

“…The preparation and physicochemical characterization of the PSi microparticles have been described in detail in the literature. 3,12,14,15,19,22 In this study, two microsized THCPSi fractions were prepared: 1Ϫ10 and 10Ϫ25 m. The average pore diameter of these particles was 9.8 nm. The specific surface area was 322 m 2 /g, and the pore volume was 0.81 cm 3 /g.…”

Section: Resultsmentioning

confidence: 99%

“…In addition, improved solubility of poorly soluble drugs after loading has been reported. 14Ϫ16 The silicon surface can be treated in the gas phase by oxidation, hydrosilylation, and thermal carbonization, 3 or it can also be grafted with numerous functional moieties, including polyethyleneglycol 17 and folate. 18 Recently, the suitability of thermally hydrocarbonized silicon (THCPSi) microparticles for peptide delivery was demonstrated.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Biocompatibility of Thermally Hydrocarbonized Porous Silicon Nanoparticles and their Biodistribution in Rats

et al. 2010

Self Cite

View full text Add to dashboard Cite

Porous silicon (PSi) particles have been studied for the effects they elicit in Caco-2 and RAW 264.7 macrophage cells in terms of toxicity, oxidative stress, and inflammatory response. The most suitable particles were then functionalized with a novel 18 F label to assess their biodistribution after enteral and parenteral administration in a rat model. The results show that thermally hydrocarbonized porous silicon (THCPSi) nanoparticles did not induce any significant toxicity, oxidative stress, or inflammatory response in Caco-2 and RAW 264.7 macrophage cells. Fluorescently labeled nanoparticles were associated with the cells surface but were not extensively internalized. Biodistribution studies in rats using novel 18 F-labeled THCPSi nanoparticles demonstrated that the particles passed intact through the gastrointestinal tract after oral administration and were also not absorbed from a subcutaneous deposit. After intravenous administration, the particles were found mainly in the liver and spleen, indicating rapid removal from the circulation. Overall, these silicon-based nanosystems exhibit excellent in vivo stability, low cytotoxicity, and nonimmunogenic profiles, ideal for oral drug delivery purposes.

show abstract

Section: Resultsmentioning

confidence: 99%

mentioning

confidence: 99%

Biocompatibility of Thermally Hydrocarbonized Porous Silicon Nanoparticles and their Biodistribution in Rats

et al. 2010

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, to reduce possible MS-MPs degradation in the aqueous solvent, and potential protein release in further studies dealing with loaded particles, the CS-coating process was limited to 1 h of co-incubation. According to a previous study [13], it is estimated that only 10% or less of the MS-MPs weight could be lost under the selected experimental conditions. Once established the optimal coating method, we investigated the effect of CS chemical properties (molecular weight, degree of acetylation) and CS concentration in the efficiency of CS incorporation into the final system.…”

Section: Ms-mpsmentioning

confidence: 99%

“…Mesoporous silicon is also biodegradable, and the kinetics of this process can be tailored both by modulating particles and size and by modifying the chemistry of its surface [11]. Overall, mesoporous silicon is attracting interest in the pharmaceutical field and several recent reviews have addressed its potential for controlled release devices [12,13].…”

Section: Introductionmentioning

confidence: 99%

Protein delivery based on uncoated and chitosan-coated mesoporous silicon microparticles

Pastor

Matveeva

Valle-Gallego

et al. 2011

Colloids and Surfaces B: Biointerfaces

View full text Add to dashboard Cite

Mesoporous silicon is a biocompatible, biodegradable material that is receiving increased attention for pharmaceutical applications due to its extensive specific surface. This feature enables to load a variety of drugs in mesoporous silicon devices by simple adsorption-based procedures. In this work, we have addressed the fabrication and characterization of two new mesoporous silicon devices prepared by electrochemistry and intended for protein delivery, namely: (i) mesoporous silicon microparticles and (ii) chitosan-coated mesoporous silicon microparticles. Both carriers were investigated for their capacity to load a therapeutic protein (insulin) and a model antigen (bovine serum albumin) by adsorption. Our results show that mesoporous silicon microparticles prepared by electrochemical methods present moderate affinity for insulin and high affinity for albumin. However, mesoporous silicon presents an extensive capacity to load both proteins, leading to systems were protein could represent the major mass fraction of the formulation. The possibility to form a chitosan coating on the microparticles surface was confirmed both qualitatively by atomic force microscopy and quantitatively by a colorimetric method.Mesoporous silicon microparticles with mean pore size of 35 nm released the loaded insulin quickly, but not instantaneously. This profile could be slowed to a certain extent by the chitosan coating modification. With their high protein loading, their capacity to provide a controlled release of insulin over a period of 60-90 min, and the potential mucoadhesive effect of the chitosan coating, these composite devices comprise several features that render them interesting candidates as transmucosal protein delivery systems.

show abstract

“…Porous silicon has been under pre-clinical evaluation for drug delivery for a number of years [1][2][3][4][5][6]. Its medical biodegradability and biocompatibility [7][8][9], widely tuneable pore sizes via electrochemical etching [10,11], flexible surface chemistry [12,13] and high payloads of nanostructured drugs [14] are its key attributes in this regard.…”

Section: Introductionmentioning

confidence: 99%

Quantification and Reduction of the Residual Chemical Reactivity of Passivated Biodegradable Porous Silicon for Drug Delivery Applications

Shabir¹,

Webb²,

Nadarassan³

et al. 2017

Silicon

View full text Add to dashboard Cite

The chemical reactivity of as-anodized porous silicon is shown to have an adverse effect on a model drug (Lansoprazole) loaded into the pores. The silicon hydride surfaces can cause unwanted reactions with actives during storage or use. Techniques such as thermal oxidation or surface derivatization can lower the reactivity somewhat, by replacing the reactive silicon-hydride species with a more benign oxide or functional group. However, by using a trio of analytical techniques (fluorometric dye assay, HPLC assay, and chemography) we show that residual hydride is still likely to be present and only after combining thermal oxidation with surface derivatization can the residual reactivity be reduced to those values typically observed with sol-gel (porous) silica. Potential sources of residual reactivity are discussed, with reference to data obtained by trace metal analysis, residual solvents, and pH measurements.

show abstract

Mesoporous Silicon in Drug Delivery Applications

Cited by 419 publications

References 165 publications

Biocompatibility of Thermally Hydrocarbonized Porous Silicon Nanoparticles and their Biodistribution in Rats

Biocompatibility of Thermally Hydrocarbonized Porous Silicon Nanoparticles and their Biodistribution in Rats

Protein delivery based on uncoated and chitosan-coated mesoporous silicon microparticles

Quantification and Reduction of the Residual Chemical Reactivity of Passivated Biodegradable Porous Silicon for Drug Delivery Applications

Contact Info

Product

Resources

About